Collaborating Authors

Scientists develop an AI that can diagnose dementia from a brain scan


Artificial intelligence has been employed in the fight against dementia by scientists who say it can diagnose the condition from a single scan of the brain. Currently in pre-clinical trials, the system has been able to diagnose dementia years before the first symptoms develop, even with no signs of damage on the scan. It currently takes multiple scans and tests to diagnose dementia, and by the time they are complete it may be too late to enact some of the remedies that can offset the condition, researchers from the Alan Turing Institute in Cambridge explained. The new system compares brain scans of those worried they might have dementia with scans from thousands of dementia patients to identify patterns. Being able to diagnose the condition early, even before any signs are visible on scans, will allow for lifestyle and medical interventions to delay the onset, according to the team.

Artificial intelligence system that could one day diagnose dementia


AI can spot patterns in brain scans that even the most experienced neurologists can't see Scientists are testing an artificial intelligence system they believe could lead to a diagnosis of dementia following a brain scan. It can also predict whether the condition will remain stable for many years, worsen gradually, or whether the patient will require immediate treatment. Currently, a number of tests and CT scans are needed to diagnose dementia. Researchers involved in the study say that early diagnosis with the system they have developed can significantly improve patients' prognosis. "If we intervene earlier, treatments can act earlier and delay the progression of the disease, and at the same time, if we intervene earlier, can prevent further damage." of the Alan Turing Institute of Artificial Intelligence and Data Science.

Scientists say new AI tool could diagnose dementia from one brain scan


Scientists at Cambridge University have developed an AI system that they believe could diagnose dementia from a single brain scan. Pre-clinical testing suggests the tech can spot signs of dementia years before symptoms develop. The system is now being evaluated in clinical trials. Attend the tech festival of the year and get your super early bird ticket now! This process can take between four to 12 weeks, according to the Alzheimer's Society.

Artificial intelligence could be used to diagnose dementia


It's been used to detect eye diseases, make medical diagnoses, and spot early signs of oesophageal cancer. Now it has been claimed artificial intelligence may be able to diagnose dementia from just one brain scan, with researchers starting a trial to test the approach. The team behind the AI tool say the hope is that it will lead to earlier diagnoses, which could improve outcomes for patients, while it may also help to shed light on their prognoses. Dr Timothy Rittman, a senior clinical research associate and consultant neurologist at the University of Cambridge, who is leading the study, told the BBC the AI system is a "fantastic development". "These set of diseases are really devastating for people," he said. "So when I am delivering this information to a patient, anything I can do to be more confident about the diagnosis, to give them more information about the likely progression of the disease to help them plan their lives is a great thing to be able to do."

Artificial Intelligence could identify dementia years before it first appears


As supercomputers take on the mighty challenge of accelerating research in the complexities of life sciences, Artificial Intelligence (AI) is not far behind. Researchers are testing a system based on AI to detect neurological disorders like dementia in just one brain scan. As researchers begin the trial of the system, currently it takes several scans and tests to diagnose dementia. An earlier diagnosis of the disorder could be life-saving and enhance treatment strategies. The team of researchers from the University of Cambridge are hopeful that the AI system will be tested in a "real-world" clinical setting on about 500 patients, in its first year of trial.